The content provided by this website is intended only for Australian healthcare professionals.
Please leave this site if you are not an Australian healthcare professional.
Clinical trials
Clinical trial data have shown subcutaneous Remsima® treament comparable to maintenance Remsima® intravenous treatment in terms of efficacy, safety and immunogenicity.1,2,3*
*In patients with rheumatoid arthritis and inflammatory bowel disease1,2,3
References
1. Remsima® Australian Product Information. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02540-1&d=202103141016933&d=20221121172310101. Last accessed: Nov 2022.
2. Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053/j.gastro.2021.02.068. Epub 2021 Mar 5. PMID: 33676969.
3. Westhovens R, ey al. Rheumatology 2020: doi: 10.1093/rheumatology/keaa580.
Abbreviations
IBD, inflammatory bowel disease; RA, rheumatoid arthritis;